Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

8
results for

"Naoshi Nishida"

Article category

Keywords

Publication year

"Naoshi Nishida"

Correspondences

Correspondence to “Critical Flaws in the Molecular Classification of HCC Based on Metabolic Zonation”
Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo
Received July 10, 2025  Accepted July 11, 2025  Published online July 14, 2025  
DOI: https://doi.org/10.3350/cmh.2025.0760    [Accepted]
  • 1,652 View
  • 12 Download
Correspondence to editorial on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”
Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo
Received April 18, 2025  Accepted April 24, 2025  Published online April 28, 2025  
DOI: https://doi.org/10.3350/cmh.2025.0435    [Epub ahead of print]

Citations

Citations to this article as recorded by  Crossref logo
  • Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography: A Potential Imaging Biomarker for Predicting Response to Combination Immunotherapy in Hepatocellular Carcinoma
    Masatoshi Kudo
    Liver Cancer.2025; 14(5): 511.     CrossRef
  • 3,507 View
  • 23 Download
  • Crossref

Original Article

Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway
Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, Kazuko Sakai, Naoto Fujiwara, Masakatsu Tsurusaki, Kohei Hanaoka, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Atsushi Takebe, Takaaki Murase, Keiko Kamei, Takuya Nakai, Ippei Matsumoto, Kazuto Nishio, Masatoshi Kudo
Clin Mol Hepatol 2025;31(3):981-1002.
Published online March 11, 2025
DOI: https://doi.org/10.3350/cmh.2024.1088
Background/Aims
Previously, we advocated the importance of classifying hepatocellular carcinoma (HCC) based on physiological functions. This study aims to classify HCC by focusing on liver-intrinsic metabolism and glycolytic pathway in cancer cells.
Methods
Comprehensive RNA/DNA sequencing, immunohistochemistry, and radiological evaluations were performed on HCC tissues from the training cohort (n=136) and validated in 916 public samples. HCC was classified using hierarchical clustering and compared with previous molecular, histopathological, and hemodynamic classifications.
Results
Liver-specific metabolism and glycolysis are mutually exclusive and were divided into two major subclasses: The “rich metabolism” subclass (60.3%) is characterized by enhanced bile acid and fatty acid metabolism, wellto-moderate differentiation, microtrabecular or pseudoglandular pattern, and homogeneous arterial-phase hyperenhancement (APHE), corresponding to Hoshida S3 with favorable prognosis. In IL6-JAK-STAT3-high (25.0%) conditions, upregulated ALB expression, enhanced gluconeogenesis and urea cycle activity, and an inflammatorymicroenvironment are observed. Conversely, the Wnt/β-catenin-high environment (19.9%) features elevated GLUL, APOB and CYP3A4 expression, frequent CTNNB1 (D32–S37) mutations, and an immune-desert/excluded phenotype. The “glycolysis” subclass (39.7%), characterized by histopathological dedifferentiation and downregulated liver-specific metabolism, encompasses subclasses with PI3K/mTOR (20.6%) and NOTCH/TGF-β (19.1%) signaling. These often exhibit TP53 mutations, macrotrabecular massive or compact patterns, inhomogeneous/rim-APHE, and high expression of hypoxia-inducible factors and glucose transporters, corresponding to Hoshida S1/2 with poor prognosis.
Conclusions
The loss of liver-specific metabolism correlates with morphological dedifferentiation, indicating cellular dedifferentiation may exhibit both physiological and pathological duality. Key signaling pathways involved in the maturation process from fetal to adult liver and zonation program may play a critical role in defining HCC diversity.

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway.”
    Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo
    Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
  • Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography: A Potential Imaging Biomarker for Predicting Response to Combination Immunotherapy in Hepatocellular Carcinoma
    Masatoshi Kudo
    Liver Cancer.2025; 14(5): 511.     CrossRef
  • 9,667 View
  • 299 Download
  • 1 Web of Science
  • Crossref
Editorials

Hepatic neoplasm

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”
    Rong-Qi Sun, Shao-Lai Zhou
    Clinical and Molecular Hepatology.2025; 31(2): e192.     CrossRef
  • Curative response to combined targeted-immunotherapy for post-hepatectomy lymph node metastasis in sarcomatoid hepatocellular carcinoma: case report and literature review
    Pan Liu, Song Zhang, Xiao-Ming Xin, Min Jing, Lie-Dong Wen, Xin Xiang, Shun-Hai Liu
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • 5,059 View
  • 37 Download
  • 2 Web of Science
  • Crossref

Hepatic neoplasm

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
    Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee
    Clinical and Molecular Hepatology.2025; 31(1): e84.     CrossRef
  • T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells
    Thikra Majid Muhammed, Saade Abdalkareem Jasim, Ahmed Hussein Zwamel, Safia Obaidur Rab, Suhas Ballal, Abhayveer Singh, Anima Nanda, Subhashree Ray, Ahmed Hjazi, Hatif Abdulrazaq Yasin
    Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(8): 10007.     CrossRef
  • Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”
    Naoshi Nishida
    Clinical and Molecular Hepatology.2025; 31(2): 635.     CrossRef
  • Addressing the Complexities of Pre-Liver Transplant Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Response to Recent Commentaries
    Mohammad Saeid Rezaee-Zavareh, Zhiyong Guo, Ju Dong Yang
    Journal of Hepatology.2024;[Epub]     CrossRef
  • 5,844 View
  • 82 Download
  • 3 Web of Science
  • Crossref

Hepatic neoplasm

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
    Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
    Clinical and Molecular Hepatology.2024; 30(4): 1005.     CrossRef
  • 6,416 View
  • 115 Download
  • 1 Web of Science
  • Crossref

Hepatic neoplasm

Metabolic disease as a risk of hepatocellular carcinoma
Naoshi Nishida
Clin Mol Hepatol 2021;27(1):87-90.
Published online December 3, 2020
DOI: https://doi.org/10.3350/cmh.2020.0302

Citations

Citations to this article as recorded by  Crossref logo
  • Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma
    Dong Hyun Kim, Eun Min Kim, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Gi Hong Choi, Sang Hoon Ahn, Hye Won Lee, Do Young Kim
    Cancers.2025; 17(4): 566.     CrossRef
  • Biosocial Determinants of Health Among Patients with Chronic Liver Disease and Liver Cancer
    Tagari Samanta, Jun Hyoung Park, Benny Abraham Kaipparettu
    Cancers.2025; 17(5): 844.     CrossRef
  • Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an analysis from the GBD 2021 and forecast to 2050
    Jianing Shi, Xuan Wu, Jiali Yu, Qingli Zhou
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Large duct primary sclerosing cholangitis with or without inflammatory bowel disease in Saudi patients
    Hamdan S. AlGhamdi, Nawaf M. AlYahya, Ibrahim M. Bahabri, Majed A. Al Ashaikh, Abdulrahman K. Habib, Abdulaziz A. AlAhmary, Nuha Al Ajlan, Abdulrahman I. AlAbdulgader, Abduljaleel M. Alalwan, Faisal M. Sanai
    Saudi Journal of Gastroenterology.2025; 31(6): 356.     CrossRef
  • Nanoquercetin and Extracellular Vesicles as Potential Anticancer Therapeutics in Hepatocellular Carcinoma
    Alok Raghav, Goo Bo Jeong
    Cells.2024; 13(7): 638.     CrossRef
  • Hepatitis B-related hepatocellular carcinoma: classification and prognostic model based on programmed cell death genes
    Jinyue Tian, Jiao Meng, Zhenkun Yang, Li Song, Xinyi Jiang, Jian Zou
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Burden of uterine cancer in China from 1990 to 2021 and 15-year projection: a systematic analysis and comparison with global levels
    Zhan Lin, Mei Gan, Xiangping Wang, Zhonghua Su
    Reproductive Health.2024;[Epub]     CrossRef
  • Recent Trends in Liver Cancer: Epidemiology, Risk Factors, and Diagnostic Techniques
    Shivani R Kale, Geeta Karande, Anand Gudur, Aishwarya Garud, Monika S Patil, Satish Patil
    Cureus.2024;[Epub]     CrossRef
  • Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
    Seren M. Gedallovich, Paul Y. Kwo
    Clinical and Molecular Hepatology.2024; 30(4): 1050.     CrossRef
  • The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(1): 99.     CrossRef
  • Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
    Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
    Clinical and Molecular Hepatology.2023; 29(2): 433.     CrossRef
  • Occurrence of Liver Cancer in People without Traditional Risk Factors
    Junho Choi, Joohyun Park, Jae Kwang Lee, Kyunghee Cho
    Korean Journal of Clinical Geriatrics.2023; 24(1): 41.     CrossRef
  • The Role of the Gut Microbiome and the Hepatic Axis in the Pathogenesis of Metabolic Syndrome and Therapeutics
    K. P. Divya, Parneet Hari, Navjot Kanwar, Navita Aggarwal, Preeti Singh Dhoat, Lu Liu, Abhinav Kanwal, Shailendra Pratap Singh, Jiong Yu
    Advanced Gut & Microbiome Research.2023; 2023: 1.     CrossRef
  • Bursatella leachii Purple Ink Secretion Concentrate Exerts Cytotoxic Properties against Human Hepatocarcinoma Cell Line (HepG2): In Vitro and In Silico Studies
    Zeyad I. Alehaideb, Anuradha Venkatraman, Mahadev Kokane, Syed Ali Mohamed, Saranya Rameshbabu, Rasha S. Suliman, Sahar S. Alghamdi, Hamad Al-Eidi, Bandar Alghanem, Maha-Hamadien Abdulla, Sabine Matou-Nasri
    Molecules.2022; 27(3): 826.     CrossRef
  • The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study
    Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Association between metabolic syndrome, C-reactive protein, and the risk of primary liver cancer: a large prospective study
    Mengmeng Song, Tong Liu, Hai Liu, Qi Zhang, Qingsong Zhang, Yiming Wang, Xiangming Ma, Liying Cao, Hanping Shi
    BMC Cancer.2022;[Epub]     CrossRef
  • Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease
    Joo Hyun Oh, Je Hee Lee, Min Seok Cho, Hyeree Kim, Jongsik Chun, Joon Hyeok Lee, Yeup Yoon, Wonseok Kang
    Nutrients.2021; 13(3): 1013.     CrossRef
  • Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
    Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
    Cancers.2021; 13(14): 3424.     CrossRef
  • Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer
    Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro
    Translational Oncology.2021; 14(9): 101158.     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • 8,095 View
  • 126 Download
  • 20 Web of Science
  • Crossref

Hepatic neoplasm

Long-term prognosis and management of hepatocellular carcinoma after curative treatment
Naoshi Nishida
Clin Mol Hepatol 2020;26(4):480-483.
Published online September 21, 2020
DOI: https://doi.org/10.3350/cmh.2020.0208

Citations

Citations to this article as recorded by  Crossref logo
  • Prognostic nomogram based on coagulation for individualized prediction after radical resection of hepatocellular carcinoma
    Ming Lu, Haibo Yuan, Mengjie Wu, Heng Li, Congyin Tu, Kongwang Hu
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Statistical Cure After Hepatectomy for Hepatitis B Virus-Associated Hepatocellular Carcinoma: A Risk-Stratification Model
    Yi-Fan Li, Lan-Qing Yao, Chao Li, Hong Ren, Jin-Bo Gong, Han Wu, Li-Hui Gu, Ying-Jian Liang, Yu-Ze Yang, Kong-Ying Lin, Zi-Qiang Li, Qi-Xuan Zheng, Ting-Hao Chen, Ya-Hao Zhou, Hong Wang, Hong-Wei Guo, Jia-Hao Xu, Zhong Chen, Feng Shen, Ming-Da Wang, Tian
    Annals of Surgical Oncology.2025; 32(6): 4396.     CrossRef
  • Magnetic resonance elastography as a preoperative assessment for predicting intrahepatic recurrence in patients with hepatocellular carcinoma
    Jeong Hyun Lee, Jeong Ah Hwang, Kyowon Gu, Jaeseung Shin, Seungchul Han, Young Kon Kim
    Magnetic Resonance Imaging.2024; 109: 127.     CrossRef
  • Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma
    Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang, Seung Up Kim
    European Journal of Gastroenterology & Hepatology.2023; 35(2): 191.     CrossRef
  • Development and validation of a nomogram for survival prediction in hepatocellular carcinoma after partial hepatectomy
    Yang Lu, Shuang Ren, Jianning Jiang
    BMC Surgery.2023;[Epub]     CrossRef
  • Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
    Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2023; 29(3): 593.     CrossRef
  • Diagnosis of primary clear cell carcinoma of the liver based on Faster region-based convolutional neural network
    Bin Liu, Jianfei Li, Xue Yang, Feng Chen, Yanyan Zhang, Hongjun Li
    Chinese Medical Journal.2023; 136(22): 2706.     CrossRef
  • Ketogenic Diets and Hepatocellular Carcinoma
    Yan Lan, Chaonan Jin, Pavitra Kumar, Xia Yu, Cameron Lenahan, Jifang Sheng
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Prognostic significance of combined α-fetoprotein and CA19-9 for hepatocellular carcinoma after hepatectomy
    Jie Zhang, Shang Dong Qin, Yan Li, Fei Lu, Wen Feng Gong, Jian Hong Zhong, Liang Ma, Jing Fei Zhao, Guo Hua Zhan, Peng Zhan Li, Bin Song, Bang De Xiang
    World Journal of Surgical Oncology.2022;[Epub]     CrossRef
  • Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant
    Pil Soo Sung, Ji Won Han, Changho Seo, Joseph Ahn, Soon Kyu Lee, Hee Chul Nam, Ho Joong Choi, Young Kyoung You, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Does Neutrophil to Lymphocyte Ratio Have a Role in Identifying Cytokeratin 19-Expressing Hepatocellular Carcinoma?
    Chao-Wei Lee, Sey-En Lin, Ming-Chin Yu, Hao-Wei Kou, Cheng-Han Lee, Tony Kuo, Kuan-Chieh Lee, Hsin-I Tsai
    Journal of Personalized Medicine.2021; 11(11): 1078.     CrossRef
  • Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
    Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
    International Journal of Molecular Sciences.2021; 22(19): 10271.     CrossRef
  • 8,527 View
  • 105 Download
  • 14 Web of Science
  • Crossref